Recurrent Metastatic High-Grade Osteosarcoma: Disease Stabilization and Successful Pregnancy Outcome following Aggressive Multimodality Treatment

Monica Khurana; Barbara Gruner; Bindu Kanathezhath Sathi

doi:10.4103/ijmpo.ijmpo_83_17

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(04): 530-532
DOI: 10.4103/ijmpo.ijmpo_83_17

Case Report

Recurrent Metastatic High-Grade Osteosarcoma: Disease Stabilization and Successful Pregnancy Outcome following Aggressive Multimodality Treatment

Monica Khurana

Department of Hematology/Oncology, UCSF Benioff Children’s Hospital Oakland, Oakland, California 94609, USA

Department of Hematology/Oncology, Indiana University School of Medicine, Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana 46202, USA

,

Barbara Gruner

Department of Pediatric Hematology/Oncology, University of Missouri School of Medicine, Columbia, Missouri 65201, USA

,

Bindu Kanathezhath Sathi

Department of Hematology/Oncology, UCSF Benioff Children’s Hospital Oakland, Oakland, California 94609, USA

Department of Pediatric Hematology/Oncology, University of Missouri School of Medicine, Columbia, Missouri 65201, USA

› Institutsangaben

Abstract

Prognosis for refractory/recurrent metastatic osteosarcoma (OS) remains dismal with 3-year survival rates <20%. Achievement of more than 5 years of stable, refractory/recurrent metastatic OS disease in our patient is itself unique and attributable to multimodality therapy. Her high-dose chemotherapy regimen with alkylating agents did not lead to infertility, making her case even more unique. Successful disease stabilization and pregnancy outcome in our patient with metastatic multiple relapsed OS is one of the first cases published. We need further understanding and exploration of pathogenesis, chemoresistant mechanisms, and multimodality therapies including immunotherapy for OS.

Keywords

Cancer therapy - fertility - osteosarcoma

Volltext

Referenzen

References
1 Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A. et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012; 2012: 704872
2 The European and American Osteosarcoma Study, Treatment. Available from: http://www.ctu.mrc.ac.uk/euramos/about_o_treatment.asp. [Last accessed on 2013 Mar 13].
3 A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (IND#12697). The Children’s Oncology Group. 06 September, 2011. Available from: https://www.members.childrensoncologygroup.org/Prot/AOST0331/AOST0331DOC.pdf. [Last accessed on 2013 Jul 04].
4 Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S. et al. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer 2010; 54: 350-4
5 Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994; 12: 2614-20
6 Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, Charles A. et al. Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol 2012; 30: 4141-7
7 Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX. et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2014; 61: 452-6
8 Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S. et al. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer 2015; 121: 1223-30
9 Grignani G, Palmerini E, Ferraresi V, D’Ambrosio L, Bertulli R, Asaftei SD. et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: A non-randomised phase 2 clinical trial. Lancet Oncol 2015; 16: 98-107
10 Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM. et al. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: A Children’s Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res 2013; 19: 6578-84
11 A Study of Bevacizumab, a Humanized Monoclonal Antibody against Vascular Endothelial Growth Factor (VEGF), in Combination With Chemotherapy for Treatment of Osteosarcoma. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00667342. [Last accessed on 2015 Jul 07].
12 Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM. et al. Population pharmacokinetics of bevacizumab in children with osteosarcoma: Implications for dosing. Clin Cancer Res 2014; 20: 2783-92
13 Grignani G, Palmerini E, Dileo P, Asaftei SD, D’Ambrosio L, Pignochino Y. et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study. Ann Oncol 2012; 23: 508-16
14 Osteosarcoma, American Cancer Society. Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/003129-pdf.pdf. [Last accessed on 2013 Mar 16].
15 Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC. et al. Fertility of female survivors of childhood cancer: A report from the childhood cancer survivor study. J Clin Oncol 2009; 27: 2677-85
16 Barton SE, Najita JS, Ginsburg ES, Leisenring WM, Stovall M, Weathers RE. et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: A report from the Childhood Cancer Survivor Study cohort. Lancet Oncol 2013; 14: 873-81
17 Longhi A, Pignotti E, Versari M, Asta S, Bacci G. Effect of oral contraceptive on ovarian function in young females undergoing neoadjuvant chemotherapy treatment for osteosarcoma. Oncol Rep 2003; 10: 151-5
18 Hoshi M, Takami M, Ieguchi M, Aono M, Takada J, Oebisu N. et al. Fertility following treatment of high-grade malignant bone and soft tissue tumors in young adults. Mol Clin Oncol 2015; 3: 367-74